Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | IAPP | P10997 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 4/20 | 0.38 |
| ▸ | CES1 | P23141 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28457741 | 0.82 | ALDH1A1 (0.33) | SMN1; SMN2ALDH1A1CES2CES1L3MBTL1 | |
| SCHEMBL10728992 | 0.80 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1IAPPCES2CES1 | |
| SCHEMBL28674793 | 0.80 | HSD11B1 (0.44) | HSD11B1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL1095111 | 0.79 | KEAP1 (0.46) | SMN1; SMN2ALDH1A1RAB9AMAPTGAA | |
| SCHEMBL9517922 | 0.78 | KEAP1 (0.45) | SMN1; SMN2ALDH1A1RAB9AMAPTGAA | |
| Ethane SCHEMBL28508951 | 0.77 | KDM4E (0.41) | SMN1; SMN2ALDH1A1L3MBTL1MAPTTDP1 | |
| SCHEMBL10837900 | 0.77 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1ALOX5TSHR | |
| SCHEMBL9858681 | 0.76 | KDM4E (0.43) | SMN1; SMN2L3MBTL1MAPTTDP1TSHR | |
| Acetic Acid SCHEMBL27333745 | 0.76 | CES2 (0.38) | SMN1; SMN2ALDH1A1CES2CES1L3MBTL1 | |
| SCHEMBL10732000 | 0.76 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1RAB9AMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160067351-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067351-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | PTMS, FCGR2A, FCGR3B | HSD11B1 4853/4885SMN1; SMN2 4078/4885ALDH1A1 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.